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Abstract
The PROMISE trial enrolled asymptomatic HIV-infected pregnant and postpartum women not eligible for antiretroviral 
treatment (ART) per local guidelines and randomly assigned proven antiretroviral strategies to assess relative efficacy for 
perinatal prevention plus maternal/infant safety and maternal health. The START study subsequently demonstrated clear 
benefit in initiating ART regardless of CD4 count. Active PROMISE participants were informed of results and women not 
receiving ART were strongly recommended to immediately initiate treatment to optimize their own health. We recorded 
their decision and the primary reason given for accepting or rejecting the universal ART offer after receiving the START 
information. One-third of participants did not initiate ART after the initial session, wanting more time to consider. Six ses-
sions were required to attain 95% uptake. The slow uptake of universal ART highlights the need to prepare individuals and 
sensitize communities regarding the personal and population benefits of the “Treat All” strategy.
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Introduction
Previous Antiretroviral Strategies for Pregnant 
Women
Prior to 2016, ART was reserved for HIV-infected pregnant 
women with signs of immunosuppression or clinical AIDS 
[1]. Women who were not immunocompromised received 
antiretroviral prophylaxis consisting of mono-, dual or tri-
ple antiretroviral regimens throughout pregnancy, and they 
or their infants received prophylaxis during lactation. Sig-
nificant resources were invested in educating communities 
about the immunological threshold for ART initiation and 
increasing access to CD4 cell testing in maternity clinics. 
The PROMISE study was a strategy trial designed to com-
pare these antiretroviral strategies among asymptomatic 
HIV-infected pregnant women who did not meet country 
criteria for ART initiation, assessing vertical HIV transmis-
sion during pregnancy and post-delivery, infant safety and 
maternal health.
Universal ART Approach
The current World Health Organization (WHO) recommen-
dation for women diagnosed with HIV infection in preg-
nancy is to initiate life-long triple ART regardless of clinical 
or immunological staging [2]. This “Treat All” approach 
was informed in 2015 by the START trial [3] which demon-
strated that universal ART initiation reduces the risk of HIV 
disease progression. Previously, concerns had been voiced 
about the acceptability of this approach, given the prevailing 
perception in communities that ART was reserved for people 
who were sick with low CD4 counts based on prior guidance 
[1, 2]. Similarly, the practicality of delivering such a strat-
egy on a public scale and the ability of women to adhere to 
satisfactory levels had been questioned because of multiple 
operational challenges [4–7]. * L. Stranix-Chibanda  lstranix@uzchs-ctrc.org
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PROMISE Response to START Study Results
Upon release of the START study results in July 2015, the 
PROMISE randomized interventions were immediately 
halted, and universal ART was recommended by the study 
team to all participants. Since the uptake of life-long ART 
would be relevant to ART programs that would soon incor-
porate this change, quantitative data were collected in a sys-
tematic manner from these asymptomatic women with high 
CD4 counts enrolled in a clinical trial across diverse global 
settings. We assessed the uptake of universal ART and pre-
sent reasons to either accept or decline the recommendation.
Methods
PROMISE Study Design
PROMISE was conducted at 70 research sites in 15 coun-
tries within sub-Saharan Africa, Asia and the Americas. A 
total of 5400 asymptomatic HIV-infected pregnant women 
with high CD4 counts (above 350 cells/mm3 or the treat-
ment threshold at that time) were assigned to different ARV 
strategies and followed for HIV disease progression, vertical 
transmission and safety. In settings where maternal ART 
and replacement feeding was standard, eligible women 
were randomized within 6 weeks of delivery to continue or 
stop ART and remain in follow-up for intense monitoring 
of HIV disease progression and adverse events in a proto-
col named 1077HS (for HAART standard) [8]. In settings 
where maternal ART was not standard for the prevention of 
vertical transmission, separate protocols were conducted—
1077FF and 1077BF—in formula feeding and breastfeeding 
settings, respectively. Within 1077FF/BF, pregnant women 
were randomized to triple ART or prophylaxis with zidovu-
dine throughout pregnancy and delivery in the Antepartum 
Component plus single dose nevirapine at delivery followed 
by a 2 week “tail” of tenofovir/emtricitabine [9]. Women 
who did not access HIV services in pregnancy could join 
the study around the time of delivery. Eligible mothers were 
randomized after delivery in the Postpartum Component to 
receive or not receive maternal ART. Once the period of risk 
for vertical transmission was over—at delivery for 1077FF 
and after weaning or after 18 months of study intervention, 
whichever came first, for 1077BF—women receiving ART 
were randomized in the Maternal Health Component to con-
tinue or stop ART. Enrolled women who were not eligible 
for subsequent randomizations were followed in an obser-
vational cohort through study completion.
Participants were followed at least quarterly to moni-
tor clinical, immunological and virologic status. Women 
randomly assigned to not take ART started ART once 
country criteria for treatment initiation were met. Women 
remained in PROMISE follow-up regardless of ART 
status.
Participant Tracing and Information‑Giving About 
the START Study Results
Figure 1 illustrates the timeline of events surrounding the 
action taken in response to the release of the START study 
results. The PROMISE study team directed sites to actively 
contact participants to return to the clinic to receive impor-
tant information that could influence their decision to remain 
in follow-up. The rate of return was tracked at each site to 
ensure a timely response. The study team provided a struc-
tured script of simple talking points developed with input 
from the community and sites, although not formally piloted. 
After covering the essential elements of the START study 
population and findings, the script included a recommen-
dation that all women in PROMISE take ART, seeing the 
START study had showed that it is better to start ART before 
a decline in CD4 count.
When the participants returned to the study clinic, trained 
staff revisited the content of the PROMISE informed consent 
discussion with the women, emphasizing the study rationale, 
randomizations and role of the CD4 count in determining 
eligibility for initiating ART for the purposes of maternal 
treatment. The START study talking points were then deliv-
ered in a language chosen by the participant. Women already 
receiving ART were told that they would remain on ART 
and in follow-up through scheduled study exit in September 
2016. Women not on ART were strongly advised to accept 
the offer to immediately initiate ART as the best antiretro-
viral strategy to preserve their own health. Participants were 
informed that remaining in follow-up was not dependent on 
being on ART; their willingness to continue participation 
was their choice. A discussion followed to verify compre-
hension of the implications for the individual study partici-
pant and address any questions raised.
Individual Counselling
The comprehension discussion lead into an individual coun-
selling session which followed the site’s routine counselling 
procedures. The approach adopted by the numerous counsel-
lors across the different sites was not standardized due to the 
rapid nature of the action taken, and sessions were not audio-
recorded. Women were encouraged to give their personal 
interpretation of the START results and to explore their reac-
tion to the strong recommendation for all women with HIV 
to take ART in a free-ranging discussion. They could take 
as much time as they needed in the session to work out their 
feelings about continued study participation and, if relevant, 
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to decide whether they wanted to accept or decline the offer 
of universal ART. For participants advised to initiate univer-
sal ART because of the START results, counsellors probed 
each woman to give her reasons for accepting or rejecting 
the offer, then to select her primary reason for doing so.
The study physician subsequently completed the routine 
study review and linkage with appropriate treatment services 
for those initiating ART. Participants who chose not to initi-
ate universal ART at the initial session repeated the process 
at subsequent visits scheduled quarterly until ART initiation 
or through study exit.
Data Collection and Coding
After the counselling sessions, counsellors completed a 
structured data form to capture the information delivery 
process and decisions made. They categorized the responses 
into pre-set closed options derived from study team discus-
sions with the community representatives and sites. They 
recorded additional detail as open text comments. Sites 
submitted data forms to a centralized database for analysis. 
These data forms were also completed at subsequent ses-
sions for those participants who initially declined universal 
ART. Open text comments were subsequently categorized 
by two researchers following a code book developed by con-
sensus through discussion of themes emerging from the line 
list of comments.
Statistical Methods
These data analyses were based on women in follow-up off 
ART at the time of this action and with at least one counsel-
ling session. Frequencies, means, and percentiles were used 
for descriptive purposes. T-tests compared the mean difference 
between groups. The cumulative probability of remaining off 
ART over time was estimated using the Kaplan–Meier method. 
Sensitivity analyses were performed by using the antiretroviral 
drug record in place of the counselling form, with the conclu-
sion that the analysis is robust to missing counselling session 
forms (data not shown). Analyses were performed using SAS 
version 9.4. P-values less than 0.05 were considered to be sta-
tistically significant.
Based on these data generated from a large, multi-site clini-
cal trial population with prior access to intense HIV disease 
monitoring and extensive counselling services, we report the 
uptake of universal ART over time by women not receiving 
ART at the time the START study results were communicated. 
We describe the primary reasons women gave in support of 
the decisions they made.
Fig. 1  Timeline of events in the PROMISE study and concurrent ARV guidelines
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At the start of the information and counselling sessions, 
4512 of the 5400 PROMISE participants were still enrolled 
(84%) and the remainder had been lost to follow-up. All of 
the PROMISE women had delivered the index pregnancy. 
Of these, 4211 (93%) underwent at least one standardized 
counselling session. At the time of the initial session, the 
average duration of follow-up in PROMISE was 2.8 years 
(range 1–6 years), which reflects the minimum time they had 
knowledge of their HIV status. Two thousand seven hundred 
and nineteen women were on ART (65%). The remaining 
1492 women (35%) were not on ART, as they did not meet 
the local criteria at that time and had not been randomized 
to an ART study arm.
Baseline Characteristics and Health Status at Initial 
Session
Eighty-five percent of those who were not on ART and 
offered universal ART were Black or African American and 
14% identified as Hispanic or Latina. Participants were from 
Sub-Saharan Africa (77%), South America (13%), Asia (7%) 
and North America (3%). The average age was 27.3 years, 
92% were in WHO Clinical Stage I, the mean [95% confi-
dence interval (CI)] CD4 count was 680.4 (667.6, 693.2) 
cells/mm3, and 26% had a HIV viral load below or equal to 
1000 copies/mL (Table 1).
Universal ART Uptake
With one counselling session, the Kaplan–Meier estimate of 
the percentage that started universal ART was 65.5% (95%CI 
63%, 68%). The average days between subsequent sessions 
was 79 days and the maximum number of sessions was six. 
The probability of being on universal ART increased after 
each subsequent session (Fig. 2): 82.6% after two counsel-
ling sessions, 87.5% after three sessions and 94.4% at study 
end 1 year later. Initial ART uptake varied widely by country 
(Table 2).
Primary Reasons Given
The primary reasons given for declining universal ART 
at the initial counselling session were wanting more time 
to consider (44%) or feeling well and knowing their CD4 
count was high (19%). A minority expressed concern about 
potential side effects of ART (8%), that taking ART would 
lead to inadvertent disclosure of HIV status (7%) and about 
committing to life-long treatment (7%). Specific barriers 
were cited in the open text comments for 95 of the 201 par-
ticipants with more detail recorded about why they wanted 
more time to consider the offer. The most frequently men-
tioned were the need to first consult significant others (32, 
34%), psychological unpreparedness to make this important 
decision (25, 26%) and being preoccupied with a social com-
mitment (6, 6%).
The primary reasons given for accepting universal ART 
at the initial counselling session were concern about health 
(46%), because of the recommendation given by the proto-
col team (36%), and concern about the CD4 count (16%) 
(Table 3). Women who selected concern about CD4 count as 
their primary reason for initiating universal ART had lower 
mean CD4 counts than women who stated that they felt well 
and knew their CD4 count was high; 617 cells/mm3 versus 
878 cells/mm3 (mean difference = − 251, t-value = − 4.96, 
p < 0.001) in 1077BF/FF and 479  cells/mm3 versus 
686 cells/mm3 (mean difference = 207, t-value = − 4.50, 
p < 0.001) in 1077HS.
Discussion
There are two important aspects of these study findings 
which are relevant to current global HIV programs, despite 
universal ART now being the global standard and the clini-
cal trial setting being better-resourced than the public health 
sector. Firstly, that life-long ART uptake was slow; five ses-
sions were required to meet the UNAIDS super-fast-track 
‘Start Free’ target to reach and sustain more than 95% of 
HIV-infected pregnant women on life-long ART [10]. Sec-
ondly, initial life-long ART uptake was similar in settings 
where ART was standard and not standard for the prevention 
of vertical HIV transmission (64% for 1077HS and 67% for 
1077BF/FF). Our study findings suggest that the the psy-
chological and social barriers to treatment readiness among 
asymptomatic women were not completely overcome in the 
well-resourced study setting.
With the progression of WHO guidelines to recommend 
universal ART for all persons living with HIV, more current 
reports indicate successful same-day ART initiation in adult 
HIV clinics and maternity settings [11–13]. However, the 
context in which treatment is started influences retention 
in care, continued ART adherence and sustained virologic 
suppression [14, 15]. The process of initiating ART is evi-
dently separate from overcoming barriers to remaining on 
ART for life.
The primary reasons given by the 65.5% who did accept 
the offer of universal ART mirror those reported in qualita-
tive studies from Malawi [16], where the perception was that 
ART was life enhancing and led to normalization of physical 
appearance. These were facilitators for ART uptake among 
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newly diagnosed HIV-infected pregnant women within the 
public sector. Similar sentiments were voiced in discussions 
published from Tanzania, Uganda and Zimbabwe [17–19], 
where strengthened health and the ability to care for their 
families was most commonly cited as a benefit of life-long 
ART use among mothers.
The women included in this analysis were drawn from 
a well-resourced clinical trial and had lived with a known 
Table 1  Characteristics 
of women not on ART at 
first counselling session by 
PROMISE protocol
One participant in WHO clinical stage IV was not on ART due to missed study visits. This woman started 
ART once the stage IV was identified
a 1077BF/FF: breastfeeding and formula feeding versions of the PROMISE protocol
b 1077HS: HAART standard version of the PROMISE protocol






 Mean (95% CI) 27.1 (26.8, 27.4) 27.9 (27.4, 28.5) 27.3 (27.1, 27.6)
 Median 26.6 27.8 26.9
 10%, 90% 20.5, 34.3 20.5, 35.6 20.5, 34.8
Ethnicity
 Not Hispanic or Latina 993 (96%) 254 (56%) 1,247 (84%)
 Hispanic or Latina 6 (1%) 197 (43%) 203 (14%)
 Patient does not know 37 (4%) 4 (1%) 41 (3%)
 Ethnicity unavailable to clinic 0 (0%) 1 (0%) 1 (0%)
Race
 Black or African American 999 (96%) 267 (59%) 1,266 (85%)
 Asian 37 (4%) 71 (16%) 108 (7%)
 White 0 (0%) 74 (16%) 74 (5%)
 Other 0 (0%) 31 (7%) 31 (2%)
 Unknown 0 (0%) 9 (2%) 9 (1%)
 More than one race 0 (0%) 3 (1%) 3 (0%)
 American Indian 0 (0%) 1 (0%) 1 (0%)
CD4 Count (cells/mm3)
 Mean (95% CI) 708.8 (694.1, 723.6) 615.6 (591.6, 639.6) 680.4 (667.6, 693.2)
 Median 665 545.5 637
 10%, 90% 455, 1,054 364, 971 406, 1,042
 ≥ 500 851 (82%) 278 (61%) 1,129 (76%)
 350–499 157 (15%) 141 (31%) 298 (20%)
 < 350 27 (3%) 35 (8%) 62 (4%)
WHO clinical stage
 Clinical stage I 941 (91%) 427 (94%) 1,368 (92%)
 Clinical stage II 81 (8%) 22 (5%) 103 (7%)
 Clinical stage III 10 (1%) 5 (1%) 15 (1%)
 Clinical stage IV 1 (0%) 0 (0%) 1 (0%)
Log viral load (copies/mL)
 Mean (95% CI) 3.6 (3.5, 3.6) 3.6 (3.5, 3.7) 3.6 (3.5, 3.6)
 Median 3.7 3.8 3.7
 10%, 90% 2.2, 4.8 2.0, 4.6 2.1, 4.7
Viral load (copies/mL)
 > 200 820 (87%) 368 (87%) 1,188 (87%)
 ≤ 200 118 (13%) 56 (13%) 174 (13%)
Viral load (copies/mL)
 > 1000 694 (74%) 316 (75%) 1,010 (74%)
 ≤ 1000 244 (26%) 108 (25%) 352 (26%)
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HIV-infected status for 1–6 years before being offered uni-
versal ART. During that time, they had remained asymp-
tomatic and received intense health education, counselling 
and support from a team of well-trained, motivated study 
personnel. Despite that considerable investment, one-third 
of the women were hesitant about initiating universal ART 
when first provided with the opportunity and a strong rec-
ommendation to do so. While this could be a reflection of 
an ineffective delivery approach, the explanations cited for 
needing more time identify specific barriers to treatment 
readiness that are less amenable to intervention at facility 
level; reasons given included being psychologically unpre-
pared to make the decision and the importance of involving 
significant others or attending to social circumstances before 
making the life-long commitment.
The need for more time to consider the offer and to 
consult with others before initiating life-long ART was 
not unexpected, given the negative stigma attached to tak-
ing ART and the fear of rejection or violence from male 
partners [20–24]—universal challenges that prevail across 
diverse health settings and cultures [25–29]. Stigma and 
low male partner involvement are commonly cited socio-
cultural barriers that hinder successful ART treatment pro-
grams for women [17, 25]. Similarly, early experiences 
from the Malawian and Swazi ‘Option B+’ programs indi-
cated sociocultural challenges with a same-day start of 
life-long ART among women learning of their HIV status 
in pregnancy [12, 26, 30]. However, the PROMISE study 
participants had been living with their HIV diagnosis for 
some time before ART initiation was recommended, were 
well engaged in care and had received significant educa-
tion about their health status and psychological support 
to overcome potential barriers to effective treatment—all 
factors that were anticipated to facilitate same-day ART 
uptake. In the era of Treat All, the importance of address-
ing such barriers in the global context should remain para-
mount to effectively increase the treatment readiness of 
women who access life-long ART to promote sustained 
virologic suppression.
The observation that 95 women (19% of decliners) 
appeared to base their decision to decline universal ART 
on their perceived good health status and high CD4 count 
illustrates the difficulty faced in changing community per-
ceptions about the role of ART in those who remain well. 
Counselling offered within the PROMISE clinical trial set-
ting was performed by trained counsellors with adequate 
time to go over an individual woman’s questions. In public 
sector antenatal settings, however, concern exists over the 
limited staff available to provide optimal counselling ser-
vices when initiating life-long ART the same day that HIV 
is identified [16, 17, 31]. Qualitative reports indicate that 
women feel rushed into making a decision to start treatment 
and would prefer more time to consult with partners and dis-
cuss their questions and fears [19, 26]. Due to the nature of 
clinical trial settings, the same does not apply to women in 
our study, yet our findings highlight similar hesitance among 
Fig. 2  Kaplan–Meier estimate 
of the probability of remaining 
off ART as a function of the 
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HIV-infected mothers to take up ART with the need to think 
more carefully about the decision cited frequently.
Apart from receiving a very high standard of care and liv-
ing with their diagnosis for some years before these events, 
the women in this analysis differ from newly-diagnosed 
women routinely given life-long ART in public maternity 
clinics because there were few with an immediate risk 
of transmitting HIV to an infant (70 were breastfeeding). 
Thus, these PROMISE participants may have had less self-
motivation to initiate HIV treatment at that particular time. 
Table 2  Kaplan–Meier estimates of the probability to subsequent uptake of universal ART by country
Probability of ART uptake (95% confidence interval)
Peru was omitted from this table because the sample size was not large enough to calculate ART uptake probability estimates
a 1077BF/FF: breastfeeding and formula feeding versions of the PROMISE protocol




1 2 3 4 5 6
Overall Overall 65.5% (63%, 68%) 82.6% (80%, 85%) 87.5% (86%, 89%) 89.2% (87%, 91%) 91.6% (90%, 93%) 94.4% (91%, 97%)
1077HSb Argentina 85.7% (63%, 98%) 85.7% (63%, 98%) 92.9% (72%, 100%)
Botswana 61.8% (54%, 70%) 79.1% (72%, 85%) 90.3% (85%, 95%) 92.3% (87%, 96%) 92.3% (87%, 96%)
Brazil 64.6% (58%, 72%) 80.3% (74%, 86%) 83.7% (78%, 89%) 85.6% (80%, 90%) 87.8% (82%, 92%)
Haiti 92.9% (72%, 100%) 92.9% (72%, 100%) 92.9% (72%, 100%) 92.9% (72%, 100%) 92.9% (72%, 100%)
Thailand 50.7% (40%, 63%) 66.7% (56%, 77%) 72.7% (62%, 83%) 74.3% (64%, 84%) 74.3% (64%, 84%) 74.3% (64%, 84%)
USA 66.7% (48%, 84%) 72.2% (53%, 88%) 72.2% (53%, 88%) 79.2% (59%, 94%) 79.2% (59%, 94%)
1077BFFFa India 83.8% (70%, 93%) 89.2% (77%, 97%) 91.9% (80%, 98%) 91.9% (80%, 98%) 91.9% (80%, 98%) 91.9% (80%, 98%)
Malawi 81.4% (76%, 86%) 91.8% (88%, 95%) 93% (89%, 96%) 93.8% (90%, 97%) 94.7% (91%, 97%) 94.7% (91%, 97%)
South Africa 48.5% (43%, 54%) 79.9% (74%, 85%) 85.2% (80%, 90%) 89.1% (84%, 93%) 93.8% (89%, 97%)
Tanzania 36.7% (22%, 56%) 46.7% (31%, 66%) 57.3% (41%, 75%) 57.3% (41%, 75%) 63.4% (45%, 81%)
Uganda 55.6% (48%, 63%) 86% (80%, 91%) 94.5% (90%, 97%) 95.1% (91%, 98%) 97.9% (95%, 99%)
Zambia 85.7% (68%, 96%) 85.7% (68%, 96%) 85.7% (68%, 96%) 85.7% (68%, 96%)
Zimbabwe 85.5% (80%, 90%) 89.7% (85%, 94%) 90.5% (86%, 94%) 91.3% (86%, 95%) 95.7% (90%, 99%)
Table 3  Primary reasons given to decline or accept the offer of universal ART at the initial counselling session
1077BF/FF 1077HS Total
N (%) N (%) N (%)
Primary reason to decline
 Wants more time to consider 155 (46%) 63 (38%) 218 (44%)
 Feels well/knows CD4 count is high 47 (14%) 48 (29%) 95 (19%)
 Concerned about potential side effects 27 (8%) 13 (8%) 40 (8%)
 Concerned about commitment to life-long ART 29 (9%) 6 (4%) 35 (7%)
 Concerned about HIV disclosure 30 (9%) 5 (3%) 35 (7%)
 Too busy with child care or other responsibilities 11 (3%) 9 (5%) 20 (4%)
 Other reason 11 (3%) 8 (5%) 19 (4%)
 Concerned about adherence 7 (2%) 12 (7%) 19 (4%)
 Knows treatment not indicated per current local standard guidelines 18 (5%) 0 (0%) 18 (4%)
 Total declined 335 (100%) 164 (100%) 499 (100%)
Primary reason to accept
 Concerned about health 321 (46%) 128 (44%) 449 (46%)
 Understands that treatment is now recommended by the PROMISE study 
team based on the START results
244 (35%) 114 (39%) 358 (36%)
 Concerned about CD4 count 112 (16%) 41 (14%) 153 (16%)
 Other reason 16 (2%) 8 (3%) 24 (2%)
 Total accepted 693 (100%) 291 (100%) 984 (100%)
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Additionally, the offer was presented to them as a choice 
they should make individually as opposed to universal ART 
being the standard of care which they would actively have to 
opt out of if they did not feel ready. Antenatal ART initiation 
for HIV-infected women is a highly acceptable biomedical 
intervention, resulting in the dramatic decline in global pedi-
atric HIV infections witnessed in the last 5 year period [32]. 
However, an evident drop in ART adherence post-delivery 
was reported from early public process indicators [23, 33] 
which could reflect low readiness to be on treatment for life 
or waning motivation among asymptomatic mothers to con-
tinue treatment to preserve their own health as their infants 
age. Indeed, in a sample of HIV-infected women interviewed 
in Uganda who initiated life-long ART while pregnant, the 
main motivation to initiate and adhere to ART was the desire 
to have an HIV-free baby [25, 34].
Limitations
Although we used standardized educational materials and 
processes to provide the initial information about the find-
ings of the START study for our study participants, the 
requirement to respond rapidly to these findings prevented 
the study team from controlling the approach to its delivery. 
Also, subsequent counselling sessions were not standard-
ized. It is probable that study sites repeated the processes 
established for the initial session, however we accept that 
this failure to control how the information was delivered 
may be the reason for differential uptake across sites. Addi-
tionally, the focus of this response was to meet the ethical 
obligation to provide study participants with new informa-
tion that could influence their decision to remain on-study, 
then supporting them to sort through the implications for 
their personal situation and communicate their choice. For 
this reason, the sessions were not audio-recorded. More 
qualitative data would provide a deeper understanding of 
the decision-making process.
Conclusion
Despite removing structural and logistic challenges that hin-
der universal ART access in the public sector and providing 
intense ART education and HIV monitoring, one-third of 
these HIV-infected PROMISE participants did not feel ready 
to start universal ART for their own health. The study setting 
in which these events took place was better resourced than 
public health ART programs. Nevertheless, psychological 
and social challenges remained, and this study draws atten-
tion to their importance in determining treatment readiness.
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